Dezhan Healthcare Co Ltd
000813
Company Profile
Business description
Dezhan Healthcare Co Ltd's main business is drug research and development, production, and sales. The company's wholly-owned subsidiary Jialin Pharmaceuticals mainly engages in the research and development, production, and sale of cardiovascular drugs, the drugs being produced and sold including Ale (10mg), Alle (20mg), hydrochloric acid quercetine capsules, Van Le tablets type 1, Van Le tablets.
Contact
No. 235 Yin Chuan Road
Xinjiang
Urumqi830054
CHNT: +86 9914336078
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,054
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.70 | 45.90 | 0.50% |
| CAC 40 | 8,313.12 | 17.84 | -0.21% |
| DAX 40 | 25,352.39 | 66.15 | 0.26% |
| Dow JONES (US) | 49,442.44 | 292.81 | 0.60% |
| FTSE 100 | 10,238.94 | 54.59 | 0.54% |
| HKSE | 26,795.31 | 128.31 | -0.48% |
| NASDAQ | 23,530.02 | 58.27 | 0.25% |
| Nikkei 225 | 53,936.17 | 174.33 | -0.32% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,944.47 | 17.87 | 0.26% |
| S&P/ASX 200 | 8,903.90 | 48.10 | 0.54% |
| SSE Composite Index | 4,101.91 | 10.69 | -0.26% |